- Home
- GLPG vs XMTR Comparison
GLPG vs XMTR Comparison
Compare GLPG & XMTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLPG
- XMTR
- Stock Information
- Founded
- GLPG 1999
- XMTR 2013
- Country
- GLPG Belgium
- XMTR United States
- Employees
- GLPG N/A
- XMTR N/A
- Industry
- GLPG Biotechnology: Pharmaceutical Preparations
- XMTR Industrial Machinery/Components
- Sector
- GLPG Health Care
- XMTR Technology
- Exchange
- GLPG Nasdaq
- XMTR Nasdaq
- Market Cap
- GLPG 2.0B
- XMTR 1.6B
- IPO Year
- GLPG 2005
- XMTR 2021
- Fundamental
- Price
- GLPG $33.01
- XMTR $31.18
- Analyst Decision
- GLPG Sell
- XMTR Buy
- Analyst Count
- GLPG 4
- XMTR 11
- Target Price
- GLPG $25.33
- XMTR $34.82
- AVG Volume (30 Days)
- GLPG 372.1K
- XMTR 582.3K
- Earning Date
- GLPG 07-23-2025
- XMTR 08-05-2025
- Dividend Yield
- GLPG N/A
- XMTR N/A
- EPS Growth
- GLPG N/A
- XMTR N/A
- EPS
- GLPG N/A
- XMTR N/A
- Revenue
- GLPG $323,674,692.00
- XMTR $573,810,000.00
- Revenue This Year
- GLPG $0.78
- XMTR $21.50
- Revenue Next Year
- GLPG N/A
- XMTR $17.08
- P/E Ratio
- GLPG N/A
- XMTR N/A
- Revenue Growth
- GLPG 5.43
- XMTR 19.35
- 52 Week Low
- GLPG $22.36
- XMTR $11.33
- 52 Week High
- GLPG $33.86
- XMTR $45.33
- Technical
- Relative Strength Index (RSI)
- GLPG 67.37
- XMTR 41.41
- Support Level
- GLPG $31.98
- XMTR $31.44
- Resistance Level
- GLPG $33.66
- XMTR $33.55
- Average True Range (ATR)
- GLPG 0.85
- XMTR 1.68
- MACD
- GLPG 0.17
- XMTR -0.39
- Stochastic Oscillator
- GLPG 88.39
- XMTR 6.06
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
About XMTR Xometry Inc.
Xometry Inc is engaged in providing AI-enabled manufacturing equipment. Its buyers include engineers, product designers, procurement and supply chain personnel, inventors, and business owners. The manufacturing processes offered by the company include CNC Machining, Injection Molding, Urethane Casting, 3D Printing, and Die Casting. The company is organized into two segments referred to as the U.S. and the International. The majority of its revenue is derived from the U.S. segment.